New HIPAA Final Rule: Key Changes to Reproductive Health Care Privacy - Thought Leaders in Health Law®
Early Returns Podcast with Jan Baran - Josh Gerstein: SCOTUS, the Presidential Immunity Case Fallout, and the Dobbs Case Leak Investigation
Podcast: Post-Dobbs - One Year Later - Diagnosing Health Care
#WorkforceWednesday: Employee and Health Benefits One Year After Dobbs - Employment Law This Week®
Reproductive Rights in the Post-Dobbs Era
Podcast: Post-Dobbs - Considerations for Clinical Trials and Research - Diagnosing Health Care
#WorkforceWednesday: 2022 – A Year in Review - Employment Law This Week®
Season Three Trailer
Let's Talk About Child Custody & Adoption in Light of the Dobbs Decision
Podcast: Post-Dobbs Access to Reproductive Health Care and Abortion-Inducing Drugs - Diagnosing Health Care
In the Boardroom With Resnick and Fuller - Episode 2
Podcast: Post-Dobbs - Navigating the Fast-Changing and Uncertain Legal Landscape - Diagnosing Health Care
Let's Talk About the Constitutional Aspects of the Dobbs Decision
What Can The Handmaid’s Tale Teach Us About Corporate Abortion Policies? - Hiring to Firing Podcast
#WorkforceWednesday: Enforcement Risk Post-Roe, 11th State Passes Paid Family and Medical Leave, FTC/NLRB Join Forces - Employment Law This Week®
Employee Benefits Post-Dobbs: What Kinds of Assistance Can Employers Now Offer in Reproductive Healthcare?
#WorkforceWednesday: Employers Respond to Dobbs, Implications of the Supreme Court's EPA Ruling, and Pay Increases for CA Health Care Workers - Employment Law This Week®
How the Dobbs Supreme Court Decision Affects Employee Benefits
Employment Law Now VI-118 - Overturning Roe v. Wade and the Impact on Employers and Employees
DE Under 3: Federal Agencies Semi-Annual Regulatory Agenda; ODEP’s NDEAM 2022 Theme & The Dobbs Decision
Mifepristone is safe for now. On June 13, 2024, the Supreme Court unanimously held that the plaintiffs — doctors and medical associations alike — lacked standing to challenge 2000 and 2019 FDA approvals of mifepristone (brand...more
On Thursday, June 13, the Supreme Court maintained access to the abortion pill, mifepristone. This medication, in conjunction with misoprostol, was used in nearly two-thirds of all U.S. abortion and miscarriage treatments...more
We are entering a strange new world where there are evolving questions about whether assets and rights are federally regulated or state managed. Some of this is traceable to Dobbs v. Jackson Women’s Health, the case that...more
On March 26, 2024, the Supreme Court heard arguments in the two consolidated cases concerning access to mifepristone pending before the Court, FDA v. Alliance for Hippocratic Medicine, Case No. 23-235 and Danco Laboratories,...more
The Big Picture - On December 13, 2023, the Supreme Court announced its intention to review the August 16 ruling by the Fifth Circuit in Alliance for Hippocratic Medicine (AHM) v. U.S. Food and Drug Administration, et al....more
Nearly three months after hearing oral arguments, a divided Fifth Circuit panel issued its decision in Alliance for Hippocratic Medicine v. FDA, upholding the U.S. Food and Drug Administration’s (“FDA”) underlying approval of...more
In this installment of our post-Dobbs risk assessment series for hospitals and academic medical centers, we consider the ongoing impact of Dobbs v. Jackson Women’s Health Organization on delivery of clinical services beyond...more
For a brief moment in time last April, the U.S. Food and Drug Administration’s (“FDA”) approval of the commonly-used abortion medication, Mifepristone, was curtailed. Just days after a Texas federal judge’s ruling suspended...more
On April 7, 2023, two federal judges in Texas and Washington State issued dueling opinions about the abortion medication Mifepristone, just hours apart. These two decisions come in the midst of growing tension about abortion...more
The Big Picture - Less than one year after the Supreme Court overturned the federal constitutional right to abortion in Dobbs v. Jackson Women’s Health Organization and “returned [the issue of abortion back] to the people...more
The U.S. Food and Drug Administration’s (“FDA”) approval of the commonly-used abortion medication, Mifepristone, has been curtailed following dueling federal court decisions in Texas and Washington. Just days after a Texas...more
On Friday, April 7, both the Northern District of Texas and the Eastern District of Washington issued decisions impacting the Food and Drug Administration’s (FDA) approval of the abortion drug mifepristone. The Texas decision...more
A coalition of 24 Democratic AGs filed an amicus brief in the U.S. Court of Appeals for the Fifth Circuit, urging the court to stay pending the appeal of a district court’s ruling that, if allowed to take full effect, would...more
The US Supreme Court’s June 2022 decision in Dobbs v. Jackson Women’s Health Organization — which overturned Roe v. Wade and nearly 50 years of a federal constitutional right to abortion — has had a tectonic impact. Less than...more
Seyfarth Synopsis: In an anticipated decision, released late on Friday April 7, 2023 of the Easter weekend, Texas District Court Judge Kacsmaryk has halted the FDA’s approval of Mifepristone. While in Washington State,...more
Forty-four AGs, evenly split into two groups of 22, have filed briefings in a Texas lawsuit in which a conservative group is challenging the FDA’s approval of mifepristone, the drug used in medication abortions....more
The Food and Drug Administration (the “FDA”) has approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy (“REMS”) Program, increasing the accessibility of mifepristone for patients with a...more
On January 3, 2023, FDA released an updated Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. The updated REMS follows a December 2021 FDA announcement that it would eliminate the requirement that mifepristone...more
On January 3, the Biden Administration took additional steps to ease access to FDA-approved abortion medication in the United States, further wading into the legal and political chaos that has sprung up in the wake of the...more
The federal government started 2023 by clarifying important legal issues surrounding the use of medications for abortions. These changes come after much uncertainty—and controversy—around the availability of medication...more
On January 3, 2023, the U.S. Food and Drug Administration (FDA) modified its risk evaluation and mitigation strategy (REMS) program (“Mifepristone REMS Program”) to provide a process for pharmacies to become certified to...more
Editor’s Note: To help you easily access all of Manatt Health’s thought leadership on Dobbs and other reproductive health issues, we have created a new Reproductive Health “hot topics” page on our website. Now one click takes...more
We are pleased to present our annual End of Year Plan Sponsor “To Do” Lists. This year, we present our “To Do” Lists in four separate Employee Benefits Updates. This Part 1 covers year-end health and welfare plan issues....more
SAFE INTERNET SEARCHES AND PHONE CALLS- If I’m researching abortion online, are there ways to keep my searches private? Before you read these FAQs, you might want to educate yourself on how to keep your data more private....more
In light of the U.S. Supreme Court's recent decision in Dobbs v. Jackson Women's Health Organization, which returned the right to enact laws regarding reproductive health care to the states, many health care providers are...more